Frontlight ResearchEarly access
Taking people in NetherlandsPhase 4
Studies how pneumococcal vaccines act in lymph nodes across ages and HIV
Compares lymph node immune response to pneumococcal vaccines in younger, older and HIV-positive adults.
Key facts
- Who runs it
- Academisch Ziekenhuis Leiden
- Where
- Leiden, NetherlandsSee the site
- Trial code
- Registry title
- The impact of vaccine platform, age and HIV infection on germinal centre formation.
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 75 people, planned
- Started
- 6 Mar 2025
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional
- Record updated
- 31 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for generally healthy adults aged 20-40 or over 60, and adults aged 20-40 living with HIV whose virus is controlled by treatment.
- Age
- 20 - 40 years, or over 60 years (HIV group: 20 - 40 years)
- Sex
- Men and women can join.
- Disease stage
- HIV group: documented HIV infection with the virus under control (HIV copies < 200/ml).
- Earlier treatment
- HIV group: must be on active anti-retroviral therapy. No earlier pneumococcal vaccination and no earlier pneumococcal infection.
- Biomarker or test result
- HIV group: HIV copies < 200/ml.
Main reasons for not taking part
- Pregnancy at time of inclusion, or breastfeeding during the study
- Use of immunosuppressive medication
- Use of blood thinners such as DOACs or vitamin K antagonists
- Known hypersensitivity to vaccine components
- A primary immune disorder or primary coagulopathy
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age between 20 - 40 years or age > 60 years
- Generally Healthy
- For PLWH group: aged 20 - 40 years, with documented HIV infection on active anti-retroviral therapy resulting in viral supression ( HIV copies < 200/ml)
Who cannot take part
- Use of immunosuppressive medication
- Use of direct acting anticoagulant drugs (DOACs) or vitamin K antagonists
- Recent (past month) surgery in axillar area or major surgery elsewhere
- Chronic nasal corticosteroid use (> 3 months)
- Vaccination < 1 month before inclusion
- Prior documented pneumococcal vaccination
- Prior pneumococcal infection
- Known hypersensitivity to vaccine components
- History of severe nose bleeds
- Documented primary immune disorder or primary coagulopathy
- Pregnancy at time of inclusion
- Fever at time of inclusion
- Inability to provide informed consent
- Inability to visit the LUMC for study procedures
- Breastfeeding during the course of the study
Where in Netherlands
- Leids Universitair Medisch Centrum (LUMC)Leiden, NetherlandsTaking people
About the trial
What the trial wants to find out
The primary objective of the trial will be to compare germinal centre formation after pneumococcal vaccination between different populations (health young vs healthy older adults; healthy young vs people living with HIV) as well as between different vaccine platforms.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Using lymph nOde fine needle aspiration to assess the effeCt of pnEumococcal vAcciNe platform, Age and HIV infection on Germinal cEntre formation (OCEAN-AGE)
- Plain-language title
- Studies how pneumococcal vaccines act in lymph nodes across ages and HIVGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 31 January 2025